AOTMiT: Transparency Council on drug-resistant depression and endometrial cancer, among others

The agenda includes:

Preparation of an opinion on the appropriateness of inclusion in the list of prescription medical devices:

(a) medical edge filters over 400 nm without polarization in the patient population with:

Macular and other retinal diseases

diseases of the optic nerve

albinism

pseudoafacia

achromatopsia

aniridia

cataract

glaucoma

(b) medical edge filters over 400 nm with polarization in the patient population with:

Macular degeneration and other retinal diseases

optic nerve atrophy

albinism

seudoafakia

pofotochemioterpii

Preparation of a position paper on the legitimacy of the qualification as a guaranteed service in the field of psychiatric care and addiction treatment, provided in an outpatient setting, of the health care service "Combined treatment of severe drug-resistant depression (ICD-10: F33.1, F33.2), with esketamine nasal spray".

Preparation of positions on drug evaluation:

Jemperli (dostarlimabum) under the drug program "Treatment of patients with endometrial cancer (ICD-10 C54)."

Dysport (toxinum botulinicum typum A ad iniectabile) under drug program B.57. "Treatment of upper and/or lower limb spasticity after stroke with botulinum toxin type A (ICD-10 I61, I63, I69)."

Preparation of a position paper on the evaluation of Influvac Tetra (vaccinum influenzae inactivatum ex corticis antigeniis praeparatum, influenza vaccine, surface antigen), for the indication: prophylaxis of influenza, especially in people at increased risk of post-influenza complications.

Preparation of an opinion on the continuation of coverage of medicines containing the active substance pregabalinum in the indication: neuropathy in children under 18 years of age.

Source: AOTMiT